A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT05559359 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05559359
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-18
- Primary completion
- 2026-01-14
- Enrollment
- 377
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.